Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS) -- Ignore unavailable to you. Want to Upgrade?

To: Nancy McKinney who wrote (3767)	10/14/1999 1:10:00 PM
From: Hogger	Read Replies (1) \| Respond to of 4028

Nancy, my dear lady, Boris just posted this on RB: Weed 'um and reap ... ragingbull.com ( BW)(TX-CRYOGENIC-SOLUTIONS)(CYGS) CYGS Expands Antisense Patent Portfolio Business Editors/High Tech Writers HOUSTON--(BUSINESS WIRE)--Oct. 14, 1999--Cryogenic Solutions Inc. (OTCBB:CYGS)and InGene Inc have together filed a total of three new U.S. patent applications, all of which enhance and expand the single stranded DNA intracellular expression vector (ssDNAev) technology that is the centerpiece of the CYGS patent portfolio. Two of the patent applications were filed by InGene Inc., the principal research facility for the ssDNAev technology licensed exclusively to CYGS. One patent application was filed for an improved ssDNA expression vector invented jointly by CYGS and InGene personnel. In January 1999 the USPTO sent notice of allowance of all the claims in the original patent application which is expected to be issued shortly. Studies now in progress at several universities, independent laboratories, and biotech companies continue to demonstrate the ability of the CYGS vector to synthesize single strands of sequence specific DNA in the nucleus of selected cell lines for Antisense purposes. The success of genetically based Antisense Therapy depends on the ability to "deliver" specific oligodeoxyribonucleotides (ODNs) into the nucleus of infected or impaired cells where they intercept and disable messenger RNA (mRNA) molecules. The role of mRNA is to program the cytoplasm to produce the harmful proteins that actually cause the symptoms and the damage that characterizes the disease. Antisense Therapy differs from Gene Therapy in that the Antisense ODNs do not in any way alter the human genomic structure. Antisense and other genetically based therapies have the potential to shift the emphasis of healthcare from palliative to prevention; that is, from simply treating symptoms to actually eliminating disease. There are already over six hundred Antisense ODNs that have been identified and patented by various biotech companies and universities that can be used to treat over a thousand diseases. The principal limiting factor has been the problem of "delivering" the ODN into cells intact and in sufficient quantities to be effective. The CYGS vectors solve this problem by actually synthesizing the designated ODNs in the nucleus of the targeted cells. Research is ongoing to continue expanding the scope and effectiveness of the CYGS vectors as well as new technologies. --30--EB/ho* CONTACT: Cryogenic Solutions Inc., Houston Dell Gibson, 713/780-1399 KEYWORD: TEXAS INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL not what I really expected, but then again, I don't know what I was really expecting. Hogger